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Acute Molecular Changes in Synovial Fluid Following Human
Knee Injury
Association With Early Clinical Outcomes
Fiona E. Watt,1 Erin Paterson,1 Andrew Freidin,1 Mark Kenny,2 Andrew Judge,3
Jeremy Saklatvala,1 Andy Williams,4 and Tonia L. Vincent1
Objective. To investigate whether molecules
found to be up-regulated within hours of surgical joint
destabilization in the mouse are also elevated in the
analogous human setting of acute knee injury, how this
molecular response varies between individuals, and
whether it is related to patient-reported outcomes in the
3 months after injury.
Methods. Seven candidate molecules were ana-
lyzed in blood and synovial fluid (SF) from 150 partici-
pants with recent structural knee injury at baseline (<8
weeks from injury) and in blood at 14 days and 3
months following baseline. Knee Injury and Osteoarthritis
Outcome Score 4 (KOOS4) was obtained at baseline and 3
months. Patient and control samples were compared using
Meso Scale Discovery platform assays or enzyme-linked
immunosorbent assay.
Results. Six of the 7 molecules were significantly
elevated in human SF immediately after injury:
interleukin-6 (IL-6), monocyte chemotactic protein 1,
matrix metalloproteinase 3 (MMP-3), tissue inhibitor of
metalloproteinases 1 (TIMP-1), activin A, and tumor
necrosis factor–stimulated gene 6 (TSG-6). There was
low-to-moderate correlation with blood measurements.
Three of the 6 molecules were significantly associated
with baseline KOOS4 (those with higher SF IL-6, TIMP-
1, or TSG-6 had lower KOOS4). These 3 molecules,
MMP-3, and activin A were all significantly associated
with greater improvement in KOOS4 over 3 months, after
adjustment for other relevant factors. Of these, IL-6 alone
significantly accounted for the molecular contribution to
baselineKOOS4 and change inKOOS4 over 3months.
Conclusion. Our findings validate relevant
human biomarkers of tissue injury identified in a
mouse model. Analysis of SF rather than blood more
accurately reflects this response. The response is
associated with patient-reported outcomes over this
early period, with SF IL-6 acting as a single representa-
tive marker. Longitudinal outcomes will determine if
these molecules are biomarkers of subsequent disease
risk.
Joint injury is a well-established risk factor for
osteoarthritis (OA) (1,2). After meniscal tear requiring
surgical intervention, ;50% of individuals will develop
OA (3,4). Other substantial knee injuries, such as
intraarticular fractures or anterior cruciate ligament
(ACL) ruptures, in isolation or in combination with
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meniscal tears, also predispose to OA (5–7). However,
there are currently no prognostic biomarkers that allow
us to reliably predict which individuals with a given knee
trauma will develop ongoing symptoms and/or OA. It is
clear that surgical ACL reconstruction improves insta-
bility symptoms but does not remove the risk of post-
traumatic OA. There is a pressing clinical need to
identify the early processes in injured joints that lead to
subsequent disease, and the factors that influence them.
Quantifying an individual’s risk of OA may allow us to
intervene therapeutically in predisposed individuals.
Joint trauma is arguably an ideal experimental
setting to study early or pre-OA states. The initiating
stimulus is usually temporally defined, and validated
murine models are in widespread use, allowing investi-
gation of early disease mechanisms (8). Using one such
model, surgical destabilization of the medial meniscus
(DMM), our group has identified the transcriptional
events in the first few hours following this procedure,
which reproducibly leads within weeks to OA (9). By
microarray analysis and subsequent reverse transcriptase–
polymerase chain reaction, many genes were found to be
up-regulated following joint-destabilizing surgery (10).
These were mostly inflammatory response genes, includ-
ing cytokines such as interleukin-6 (IL-6), chemokines,
and proteases (including metalloproteinase 3 [MMP-3]
and aggrecanases capable of initiating cartilage degrada-
tion), but also several molecules with predicted anti-
inflammatory or repair functions, such as activin A, a
transforming growth factor b (TGFb) family member,
and tumor necrosis factor–stimulated protein 6 (TSG-6).
Both the transcriptional response to acute joint destabili-
zation and the extent of disease development can be
modulated by joint immobilization, sex, or varying genetic
strain, suggesting that at least some of this immediate
inflammatory gene response is necessary for, or might
predict, disease development (10,11).
Identification of biomarkers for OA has to date
focused primarily on products of matrix degradation,
and typically in cohorts of individuals with established
OA. Although some biomarkers show statistically signif-
icant associations with severity, progression, or thera-
peutic response (12,13), this field has been largely
disappointing in identifying a qualified biomarker that is
of use at the individual level, either in clinical trials or in
practice (14,15). Others have documented elevations of
Table 1. Characterization of assays for analytes*
Analyte Assay
Catalog no.,
manufacturer
Intraassay
CV, %
Interassay
CV, %
Normal range in
serum, ng/ml
Normal range
in plasma,
pg/ml
Normal
range in SF,
pg/ml
SF dilution,
fold
Activin A Human activin A
Quantikine kit
DAC00B,
R&D Systems
2.6 6.9 – 128–403 655–5,250 50
CRP Human vascular
injury II kit
K15136C-1,
MSD
8.2 15.0 0–5,000 – 110–2,670† 1,000
IL-1b Proinflammatory
9-plex ultra-
sensitive kit
K15007C-1,
MSD
8.0 0.8 – ,3 ,3 5
IL-6 Custom multiplex
kit (IL-61MCP-1)
K15007C-1,
MSD
10.8 15.7 – 0–1.49 0–19.8 5
MCP-1 Custom multiplex
kit (IL-61
MCP-1)
K151AYC-1,
MSD
6.4 21.7 – 84–499 55–487 5
MMP-3 Human MMP
3-plex ultra-
sensitive kit
K15034C-1,
MSD
6.2 19.9 5.3–32.0 – 0–231† 400
TIMP-1 Human TIMP-1 kit K151JFC-1,
MSD
6.5 8.8 211–466 – 75–745† 200
TSG-6 Custom human
TSG-6 prototype
kit
Prototype,
MSD
8.6 18.8 1.3–12.3 – 0–3.1† 4
* Immunoassays were performed using commercially available plate enzyme-linked immunosorbent assays, or electrochemiluminescence (MSD).
The latter included singleplex, multiplex, or prototype-printed assays, validated by us. Plasma or serum, depending on assay, or synovial fluid
(SF) aliquots were warmed to room temperature and gently vortexed prior to assay. Intraassay and interassay coefficients of variation (CV) of
,12% and ,25%, respectively, were established for all assays (n5 20 for intraassay CV and n5 4 or more for interassay CV). The lower and
upper limits of quantitation were calculated from standard curves of 3 validation plates. Samples below the lower limit were arbitrarily assigned
half the lower limit of quantitation as their concentration during analyses (22). Spike recoveries within 80% and 120% were deemed acceptable.
Linearity of dilution was confirmed for all 8 assays across the dilution range used. Uninjured control samples for both fluid types were assayed
and normal ranges were calculated (mean6 2SD; n5 50 for serum/plasma and n5 8 for SF). CRP5C-reactive protein; IL-1b5 interleukin-1b;
MCP-15monocyte chemotactic protein 1; MMP-35matrix metalloproteinase 3; TIMP-15 tissue inhibitor of metalloproteinases 1; TSG-
65 tumor necrosis factor–stimulated gene 6.
† The unit of measure was ng/ml.
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various inflammatory response molecules or their activ-
ity in synovial fluid (SF) after joint injury (16–23).
However, with two exceptions most of these studies
were cross-sectional and relatively small (n, 50), were
of a single injury type, and lacked associated clinical
data or the power to examine the effect of clinical vari-
ables or outcomes. Few studies have simultaneously
measured the molecule in SF and blood and in control
samples (20,22), and no studies to our knowledge have
shown associations between these measurements and vali-
dated prospective patient-reported outcomes. To date
“catabolic” or proinflammatory genes in the inflammatory
response have typically been examined, rather than those
thought to be antiinflammatory or promoting repair. For
example, activin A and TSG-6 have not been investigated
in this context.
The Knee Injury Cohort at the Kennedy (KICK)
study was undertaken to systematically test whether
acute injury response molecules that were up-regulated
in the mouse joint were also elevated following human
knee joint injury in a specifically designed prospective
human cohort. Seven molecules were selected for inves-
tigation, from our murine studies: IL-1b, IL-6, mono-
cyte chemotactic protein 1 (MCP-1), MMP-3, tissue
inhibitor of metalloproteinases 1 (TIMP-1), TSG-6, and
activin A (10). From a group of ;30 up-regulated tran-
scripts, all 7 were highly regulated in the mouse joint; all
were predicted to be secreted and therefore quantifiable
in human SF, serum, or plasma; and all had assays that
were validated by us to reliably measure the analyte in
both SF and blood (Table 1). In this study, we investi-
gated the presence of this biologic response in a human
cohort and the association of the biologic response with
clinical outcome measures over the initial months fol-
lowing a knee joint injury.
PATIENTS AND METHODS
Ethics approval. Approval for the KICK study was
given by South East London Research Ethics Committee 5
(REC reference 10/H0805/39; NCT02667756). Written
informed consent was obtained from all participants prior to
screening, in accordance with the Declaration of Helsinki.
Participants. Participants were referred for screening
by the orthopedic surgeon investigator (AW) from a popula-
tion with acute knee injury assessed by him at various sites in
London, UK. Inclusion criteria were clinically significant acute
knee injury within 8 weeks of recruitment; age 16–50 years;
knee effusion, evident clinically or by magnetic resonance
imaging (MRI); and evidence of $1 specified structural injury
on MRI (Table 2). Exclusion criteria were preexisting
advanced radiographic OA (Kellgren/Lawrence grade 3–4) of
the injured (index) knee; inflammatory/septic arthritis of the
index knee; previous or planned knee arthroplasty; active or
treated systemic inflammatory disease; recent infection; preg-
nancy; and inability to provide blood samples. Relative
exclusion criteria (at the discretion of the investigator)
included bony abnormality of the index knee; injury of other
body parts or surgery within the last 3 months; severe neuro-
logic/muscle/hip disease; significant, active comorbidity; and
contraindication for MRI.
Clinical outcomes. The Knee Injury and Osteoarthritis
Outcome Score (KOOS), from which KOOS4, a single compos-
ite score, can be calculated (an average of 4 of the 5 KOOS sub-
scales including pain, symptoms, sports/recreation, and quality
of life) (24) and Tegner score (25) were obtained at baseline and
3 months (Figure 1A). Musculoskeletal examination findings,
including knee effusion grade, were documented by the same
investigator (FEW).
Controls. Normal SF was obtained from patients
undergoing limb amputation for treatment of lower limb
tumor at RNOH Stanmore (London, UK) or transplant dona-
tion at Charing Cross Hospital (London, UK) (REC 09/
H0710/60), who had macroscopically normal knee articular
cartilage at the time of surgery and no evidence of arthritis or
tumor invasion into the joint. Of the controls who had sar-
coma, none had received chemotherapy near the time of the
sample collection (within ;6 weeks before the sample collec-
tion). Plasma and serum were obtained from consenting
healthy donors who were approximately matched with the
patients for age and sex (REC 11/H0711/17).
Samples. Biologic samples were obtained at the base-
line visit (within 8 weeks of knee injury and prior to any surgi-
cal intervention), and 14 days and 3 months after baseline
(Figure 1A). Samples included whole blood and, where there
was clinical intervention such as arthrocentesis or arthroscopy,
SF. SF was collected by needle aspiration from the joint prior
to introduction of the arthroscope. All samples were trans-
ferred to the laboratory within 2 hours. Whole blood (divided
between tubes with EDTA and plain tubes for plasma and
serum, respectively) was centrifuged at 1600g for 15 minutes at
208C. SF was centrifuged for a further 20 minutes at 3,000g.
Supernatants were stored in cryovials at 2808C in monitored
freezers.
Reagents. General laboratory reagents were the best
available grade and were from either Sigma-Aldrich or BDH
unless otherwise stated. Meso Scale Discovery (MSD) plates
and MSD Sulfo-Tag–labeled streptavidin (catalog no. R32AD-5)
were from Meso Scale Discovery. Activin A Quantikine
enzyme-linked immunosorbent assay (ELISA) was from R&D
Systems.
Assays. All assays were carried out according to the
manufacturers’ instructions unless stated otherwise. Each
assay underwent structured validation and performance assess-
ment for serum or plasma and for SF prior to use (Table 1).
ELISA plates were read using Berthold Mithras LB940, and
MSD plates were read using MSD Sector Imager 2400 and
analyzed with MSD Discovery Workbench software version 3.
For TSG-6, plates were custom-coated (MSD) with capture
antibody (anti–TSG-6) (clone NG3, MABT108; Merck
Millipore), blocked in 2% bovine serum albumin (BSA)/phos-
phate buffered saline (PBS), and washed 3 times with PBS/
0.05% Tween 20. Twenty-five microliters per well of standards
(250-0.24 ng/ml of recombinant human TSG-6) (#2104-TS-
050; R&D Systems) or samples (in Cusabio sample diluent
[MBS926793; MyBioSource]) were incubated in duplicate for
2 hours. Sulfo-Tag–labeled streptavidin (1 ml/ml) was added to
detection antibody (human TSG-6 biotinylated polyclonal
antibody [0.5 mg/ml]) (BAF2104; R&D Systems). Plates were
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washed, and 25 ml of detection solution was added per well for
2 hours. Plates were washed and incubated with 150 ml/well of
read buffer (MSD).
Data storage and statistical analysis. Power cal-
culations to allow detection of a change in outcome of
KOOS4, applying a minimum clinically important difference of
8 and SD of 15, were carried out at the initiation of the study
(24), based on a 2-sided t-test comparing high and low levels
of a particular biomarker. Fifty-six individuals in each group
(total population of 112) were adequate to give 80% power at
a 5% level of significance. Allowing for ;30% dropout, 150
individuals were recruited.
Comparison of biomarker levels between KICK partici-
pants and controls. Normality of each continuous variable was
assessed by Q–Q plots and kernel density distribution plots.
For nonparametric variables, differences between 2 groups
were compared by Mann-Whitney U test.
Change in biomarker levels over time (baseline, 14
days, and 3 months). For comparison of more than 2 groups
of normally distributed variables, repeated-measures analysis
of variance was used.
Association of biomarkers with KOOS4. The outcome
measures were KOOS4 at baseline and absolute change in
KOOS4 between baseline and 3 months. Linear regression was
used to model the relationship between biomarker levels and
the outcome variable KOOS4, adjusting for 7 predefined con-
founding variables (time from injury to sampling, extent/type
of joint injury, SF blood staining, presence of effusion, sex,
age, and body mass index [BMI]). Crude unadjusted models
describe the association of the biomarkers with the outcome,
and adjusted models were controlled for 4 significant explana-
tory variables (time from injury to sampling, extent/type of
joint injury, heavy SF blood staining, and age).
All available data from all participants from relevant
visits were analyzed. Data were stored in a secure online data-
base (System for Collaborative Translational Research
[Hospital for Special Surgery]). Analysis was performed in
Stata IC 13 (StataCorp) and GraphPad Prism 6.03.
RESULTS
Characteristics of the study population. Char-
acteristics of the 150 individuals in the cohort are shown
in Table 2. The group was young and predominantly
Table 2. Characteristics of the KICK participants and controls
KICK participants
(n5 150)
Controls (blood samples)
(n5 50)
Controls (SF samples)
(n5 8)
Age, median (range) years 25 (16–50)* 32 (21–49) 48 (41–68)
Sex, no. (%) male/female 121 (81)/29 (19) 33 (65)/17 (35) 4 (50)/4 (50)
Time from injury at baseline, median (range) days 17 (1–56) – –
Body mass index, median (range) 26 (19–39) Not available Not available
Tegner score prior to injury, median (range) 10 (3–10) – –
Tegner score at baseline, median (range) 2 (1–6) – –
Type of injury, no. (%)†
Meniscal tear 27 (18) – –
Single ligament rupture only 28 (18) – –
ACL1meniscal tear 61 (41) – –
Severe trauma 34 (23) – –
Clinical effusion at baseline‡ 145 (97) – –
SF blood staining, no. (%)§¶ –
None 42 (31) – 6 (75)
Mild 34 (25) – 2 (25)
Moderate 25 (18) – 0 (0)
Severe 26 (19) – 0 (0)
Present, ungraded 9 (7) – 0 (0)
KOOS4 at baseline, mean6 SD¶ 446 18 – –
KOOS4 at 3 months, mean6SD¶ 626 16 – –
Serum CRP at baseline, median (range) ng/ml¶ 524 (26.8–56,700) 485 (43.7–5,098) –
K/L grade at baseline, median (range)¶ 0 (0–2) Not available Not available
* P, 0.0001 versus control blood and synovial fluid (SF) samples, by Mann-Whitney test.
† Four types of injury were defined and are listed in order of increasing extent of trauma (categorized by arthroscopy where performed,
supplemented by magnetic resonance imaging [MRI] findings). Severe trauma was defined as combined ligament (.1) rupture, or fracture or
dislocation. ACL5 anterior cruciate ligament.
‡ The size of effusion was estimated clinically as small (46%), medium (39%), or large (12%). Five participants had effusions at the time of
MRI that had resolved by baseline.
§ The presence of blood staining in SF was graded subjectively under normal light conditions using a predefined visual grading scale, where
none5no visible red staining of the SF, mild5 visible red staining with a high level of translucency (finger behind tube visible with low distortion),
moderate5 heavy red staining with a low level of translucency (finger behind tube visible with high distortion), and severe5 heavy red staining and
opaque (finger behind tube not visible).
¶ SF blood staining data were available for 136 Knee Injury Cohort at the Kennedy (KICK) participants, Knee Injury and Osteoarthritis
Outcome Score 4 (KOOS4) at baseline was available for 143 KICK participants, KOOS4 at 3 months was available for 124 KICK participants,
serum C-reactive protein (CRP) levels at baseline were available for 149 KICK participants, and Kellgren/Lawrence (K/L) grade at baseline was
available for 150 KICK participants.
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male (only 29 of the 150 participants were female). The
participants’ median Tegner score prior to injury was
10, indicating a high level of physical activity (10 equates
to national elite competitive sports). Of the 150 partici-
pants, 71% were professional sports players. The major-
ity (95%; n5 143) had sustained their injury playing
sports, 76% of these playing either football or rugby.
Other modes of injury included tripping, and skiing or
ballet injuries.
Participants were recruited soon after knee
injury, with a median time from injury to baseline visit
of 17 days (Figure 1A). At baseline, the majority of
participants had moderate to severe pain in their index
knee (.4 on a scale of 0–10, with 10 indicating the worst
pain imaginable), and the KOOS4 showed significant
impairment (where 100 is normal and 0 is highly
impaired) (Table 2). All subjects had evidence of clinical
effusion at baseline, or had prior evidence of effusion on
MRI. There were a range of structural knee injuries
within the cohort; these were categorized via arthroscopic
findings (subsequently performed for clinical reasons),
supplemented by MRI findings. Injury categories are
listed in Table 2 in order of increasing extent of trauma;
injuries tended to be structurally more extensive as the
Figure 1. Analytes in the synovial fluid (SF) and blood of participants with knee injury in the Knee Injury Cohort at the Kennedy (KICK) and
healthy controls. A, Flow chart indicating the schedule of study visits in the KICK cohort over 3 months and timing of clinically indicated surgical
treatment. (Surgical interventions are detailed in Supplementary Table 1, http://onlinelibrary.wiley.com/doi/10.1002/art.39677/abstract.) The num-
bers of individuals for whom Knee Injury and Osteoarthritis Outcome Score (KOOS) data were available (at baseline and 3 months) and from
whom blood and SF samples were obtained are shown. To be eligible for the study, participants had to have sustained 1 or more of the following
injuries within 8 weeks of the baseline visit: meniscal tear, cruciate ligament rupture, colateral ligament tear, posterolateral corner injury, trau-
matic chondral defects, articular or periarticular fracture, or patellofemoral or tibiofemoral dislocation. B, Baseline levels of markers of interest
in SF and matched blood samples, either plasma (for interleukin-6 [IL-6], monocyte chemotactic protein 1 [MCP-1], and activin A) or serum (all
other markers), from KICK participants with knee injury and healthy, age- and sex-matched controls. All samples were centrifuged to remove
cells. Supernatants were measured in duplicate by electrochemiluminescence or enzyme-linked immunosorbent assay (activin A only). Values
were obtained in all participants for all SF analytes except for IL-6 and tumor necrosis factor–stimulated gene 6 (TSG-6). IL-6 levels were below
the lower limit of quantitation in 12 of 136 samples (8.8%), and TSG-6 levels were below the lower limit of quantitation in 8 of 135 samples
(6%). Measurements for each of 6 analytes are shown, plotted on a log10 y-axis. Symbols represent individual samples; horizontal and vertical
lines show the median and interquartile range. *5P, 0.05; **5P, 0.01; ***5P, 0.001; ****5P, 0.0001, by Mann-Whitney U test.
MMP-35matrix metalloproteinase 3; TIMP-15 tissue inhibitor of metalloproteinases 1. Color figure can be viewed in the online issue, which is
available at http://onlinelibrary.wiley.com/journal/doi/10.1002/art.39677/abstract.
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category increased. The most common findings were a
meniscal tear, an ACL rupture, or both. A total of 145
participants underwent surgical treatment of their injury,
140 of these ,24 hours after the baseline visit (see
Supplementary Table 1, available on the Arthritis &
Rheumatology web site at http://onlinelibrary.wiley.com/
doi/10.1002/art.39677/abstract). SF was available for 136
(91%) of the participants at baseline; some blood staining
was seen in the majority of these samples (Table 2). Data
and sample completeness at other visits are shown in
Figure 1A. There was 1 case of septic arthritis at 6 weeks,
and this participant was withdrawn from subsequent study
follow-up and from the analysis at this point.
Elevated levels of candidate molecules in SF,
but not peripheral blood, after knee injury. Levels of
6 of the 7 analytes, IL-6, MCP-1, activin A, MMP-3,
TIMP-1 and TSG-6, were significantly elevated in the
SF of KICK participants, compared with SF samples
from 8 controls (Figure 1B). However, values varied
widely between individuals, with a substantial number
Figure 2. Change in analyte levels over time in the blood of KICK participants, and correlation between analyte levels in SF and blood. A, Blood
samples, either plasma (IL-6) or serum (MMP-3 and TSG-6), from individuals with knee injury were obtained at the baseline (BL) visit (within 8
weeks of injury), and 14 days and 3 months after the baseline visit and assayed for IL-6, MMP-3, and TSG-6. Values for each individual are con-
nected by a line. IL-6 levels were below the lower limit of quantitation in 120 of 149 samples at baseline, 58 of 82 samples on day 14, and 104 of 120
samples at 3 months. TSG-6 levels were below the lower limit of quantitation in 32 of 149 samples at baseline, 17 of 53 samples on day 14, and 19 of
120 samples at 3 months. Broken lines represent the calculated upper limit of normal for each analyte. The significance of the difference over time
for each log-transformed analyte level was tested by repeated-measures analysis of variance. **5P, 0.01; ****5P, 0.0001. NS5 not significant.
B, Correlations between analyte levels in SF, serum (s), and plasma (p), were determined by performing nonparametric Spearman’s rank test on
nontransformed data. All available participant data from the baseline visit were analyzed. Values are Spearman’s R coefficient with P values in
parentheses. Shading indicates the strength of correlation. CRP5C-reactive protein (see Figure 1 for other definitions).
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lying within the normal range for some molecules, such
as IL-6 and TSG-6. IL-1b levels were below the limit of
detection for the assay for all but 1 individual (data not
shown).
In contrast, there was no significant elevation of
the analytes in the blood of KICK participants at base-
line (although some individuals had elevated IL-6 or
TSG-6 levels) (Figure 1B). Paradoxically, all analytes
except for IL-6 were significantly lower in blood from
the KICK participants than in the 50 controls.
The longitudinal response to joint injury is
detectable in peripheral blood for some molecules, but
correlates poorly with that in SF. Given the low
detectable response in the blood samples at baseline, it
was important to assess if there was delayed response in
serum or plasma at the 3-month visit. IL-6 levels were very
low or undetectable; for those with measurable levels at
baseline there was a tendency for IL-6 levels to decrease,
whereas serum MMP-3 levels increased compared with
baseline levels (Figure 2A). However, serumMMP-3 levels
were above the upper limit of normal at 3 months for only
a few individuals. All individuals who had elevated serum
TSG-6 levels at baseline continued to have significantly
elevated serum levels at 3 months. A group within the con-
trol population who had relatively higher serum levels of
TSG-6 was also evident (Figure 1B). MCP-1, activin A, and
TIMP-1 levels were low and there was very little detectable
change in blood over 3 months (data not shown).
There was moderate-to-strong correlation be-
tween the levels of several SF analytes in samples at
baseline, notably IL-6, TIMP-1, and TSG-6 (Figure
2B). In contrast, there was at best low-to-moderate cor-
relation between paired plasma or serum and SF levels
for any given analyte, except for C-reactive protein
(CRP) (Spearman’s R5 0.88, P, 0.0001) (Figure 2B).
CRP levels were not significantly elevated in the SF or
serum of those with joint injury compared with con-
trols, although a few individuals did have elevated
serum levels at baseline (Table 2). CRP levels were sub-
stantially lower in SF than in serum, likely reflecting
generation from a systemic source rather than the joint.
In view of the lack of any satisfactory surrogate blood
marker(s) for the immediate response to joint injury,
it was important to focus on the large and detectable
response in the SF.
The variation of the injury response is partly
explained by time from, and severity of, injury. It was
likely that levels of SF markers would be higher the
closer the sampling was to the time of joint injury. This
was true for all analytes. Samples obtained within 20
days of injury had the highest levels (Figure 3). MMP-3
levels appeared least affected by time from injury to
sampling. Nontransformed data are shown in Figure 3.
After log transformation of marker levels, a linear rela-
tionship with time from injury accounted for 15–30% of
the variation in markers.
Substantial interindividual variation in these SF
markers was therefore not accounted for. Log-
transformed SF analyte levels were modeled by linear
regression with 7 predefined explanatory variables: time
Figure 3. Influence of time from injury on the biologic response to injury in SF. Measurements of the levels of 6 analytes in SF obtained from
the index knee at the baseline visit were plotted on a log10 y-axis against time from injury to sampling (within 8 weeks of injury).
Nontransformed data are shown for all analytes. Symbols represent individual samples. Broken lines represent the calculated upper limit of nor-
mal for each analyte. Spearman’s R coefficient and P values are shown. See Figure 1 for definitions.
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from injury, type/extent of joint injury, presence of SF
blood staining, presence of large effusion, sex, age, and
BMI (Table 2 and Supplementary Table 2, available
on the Arthritis & Rheumatology web site at http://
onlinelibrary.wiley.com/doi/10.1002/art.39677/abstract).
Increasing extent of knee trauma was significantly asso-
ciated with increases in most analytes. The presence of
hemarthrosis (moderate or severely blood-stained SF)
and age were also significant explanatory variables for
some analytes. No significant independent effect on any
of the analytes was found for sex, BMI, or size of
effusion.
Independent association between the molecular
response to injury in SF and KOOS4. SF IL-6, TIMP-1,
and TSG-6 levels were each significantly associated with
baseline KOOS4 (Figure 4A). When all 3 markers were
added to a linear regression model of baseline KOOS4,
IL-6 alone was significant in representing the molecular
response in SF, alongside blood staining and time from
injury (coefficient 24.0 [95% confidence interval (95%
CI) 25.92, 22.08]) (adjusted R2 for model 0.30, contri-
bution of 3 analytes 0.16).
The association of each SF analyte with change
in KOOS4 over 3 months was investigated, adjusting for
Figure 4. Association of SF analyte levels, including IL-6 levels, with the clinical outcome KOOS4. A, Linear regression models of participants’
KOOS4 at baseline (top) and of the change in KOOS4 over 3 months (bottom) for each of 6 SF analytes at baseline. Forest plots of unadjusted
(crude) results are shown on the left, and forest plots of results adjusted for 4 predefined variables (time from injury, injury category, presence of SF
blood staining, and age) are shown on the right. 95% CI5 95% confidence interval. B, KOOS4 at baseline (BLKOOS4), KOOS4 at 3 months
(mKOOS4), and change in KOOS4 over 3 months (KOOSdiff) for KICK participants grouped into quartiles of SF IL-6 levels at baseline, with group
1 being the lowest quartile and group 4 being the highest quartile. Data are shown as box plots. Each box represents the 25th to 75th percentiles.
Lines inside the boxes represent the median. Lines outside the boxes represent the 10th and 90th percentiles. Symbols indicate outliers. *5P, 0.05;
**5P, 0.01 versus group 1 (lowest quartile of IL-6 levels), by Mann-Whitney U test. NS5 not significant (see Figure 1 for other definitions). Color
figure can be viewed in the online issue, which is available at http://onlinelibrary.wiley.com/journal/doi/10.1002/art.39677/abstract.
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relevant explanatory variables. In the absence of analyte
measurements, only 2% of the difference in KOOS4
over the 3 months was explained (injury category was
the only significant variable). Baseline SF IL-6, activin
A, MMP-3, TIMP-1, and TSG-6 levels were each signifi-
cantly associated with the change in KOOS4 over 3
months, whereas MCP-1 was not (Figure 4A). IL-6 lev-
els were most strongly associated with the change in
KOOS4. When all 5 of these SF analytes were included
in the linear regression model, only SF IL-6 levels were
independently associated with the change in KOOS4
(coefficient 2.80 [95% CI 0.89, 5.52]).
Participants with SF IL-6 levels in the highest
quartile had significantly lower (worse) KOOS4 at base-
line compared with individuals with IL-6 levels in the
lowest quartile, whereas these 2 groups had a similar
KOOS4 at 3 months. On average, KOOS4 increased by
10 points more over 3 months in those with IL-6 levels
in the highest quartile at baseline compared to those
with IL-6 levels in the lowest quartile at baseline (Figure
4B). The differences between those with low IL-6 levels
and those with high IL-6 levels held true if participants
were divided into subgroups based on the severity of
injury. Scores for the KOOS domains pain, symptoms,
and sports and physical activity were all significantly
reduced (worse) at baseline in those with high SF IL-6
levels (P5 0.0002, P5 0.0035, and P5 0.04, respec-
tively), and the quality of life domain score was reduced
to a lesser extent (P5 0.07).
Findings were the same if the 4 individuals from
whom SF was obtained 14 days after baseline were
included (data shown do not include these individuals). A
post hoc analysis of individuals who reported oral nonste-
roidal antiinflammatory drug (NSAID) use within 10 days
of either their baseline or 3-month visit (49 individuals),
and those who did not (101 individuals) suggested that
NSAID use had no significant effect on baseline KOOS4
(P5 0.90), 3-month KOOS4 (P5 0.60), or change in
KOOS4 (P5 0.595), or on levels of SF IL-6 (P5 0.45).
DISCUSSION
In a large cohort of participants, nearly all of
whom had paired SF and blood samples available at
baseline, we observed markedly elevated SF levels of 6 of
7 molecules that were candidates identified in a mouse
model of joint destabilization (10). These findings dem-
onstrate the commonality between themouse and human
response to joint injury and support the utility of such
preclinical models to investigate pathways in early OA.
To our knowledge, this is the largest study of its
type, systematically examining SF and blood levels of
candidate markers across a variety of knee injuries with
longitudinal follow-up. Although the levels of markers
increased with the extent of injury, the ubiquitous
nature of the response irrespective of the type of injury
was notable. Similar increases in IL-6 levels have been
reported after isolated ACL tears, ACL tears associated
with meniscal injury, and low- or high-energy intra-
articular fractures (22,26,27). It may be that the type of
joint injury, rather than its cause, is more important,
pointing to an underlying common pathologic response
to connective tissue injury. The finding that hemarthrosis
independently influences biomarker levels is consistent
with previously published results (21). Nontraumatic
hemarthrosis has historically been associated with arthri-
tis and may be proinflammatory (28,29). This is an
important consideration as clinical practice moves away
from early drainage or washout of joints to more conser-
vative approaches. Our study highlights the importance
of having a large enough cohort to adjust for such
factors.
Notably, very little of the SF response was
reflected in the paired blood samples at baseline. Our
findings are consistent with recent publications from the
Knee Anterior Cruciate Ligament, Nonsurgical versus
Surgical Treatment (KANON) cohort, which showed
levels of SF IL-6 at baseline similar to those in the
present study and increased markers of proteolysis in
the SF of 121 individuals with ACL rupture, which also
correlated poorly with levels in blood over a 5-year
period (22). A further smaller study conducted within 4
weeks of knee injury demonstrated that of 7 biomarkers
whose levels were significantly higher in SF than in
serum, there was correlation with serum levels for just 4
(20). In recent years there has been a focus on
serum and urine biomarkers for OA detection and prog-
nosis (14,15,30,31). While identification of a reliable
marker that is detectable in more accessible biologic
samples remains an important goal, ours and other
studies examining both SF and blood highlight the
potential loss in sensitivity if only blood is examined. It
may be that in a more chronic setting after injury, the
predictive value of some blood-based markers improves
(17).
This is the first study to identify TSG-6 and acti-
vin A as highly regulated molecules in SF following
human joint injury. Activin A plays a role in repair and
wound healing (32,33). We have previously shown that
it is actively synthesized by cartilage in response to
experimental injury, and that it exerts an anticatabolic
effect on IL-1–induced aggrecan degradation in vitro
(34). TSG-6 forms complexes with hyaluronan and
inter-a–inhibitor (IaI) (35,36). It reportedly protects
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against inflammatory arthritis by reducing cartilage and
bone turnover (37). Genome-wide linkage analyses
associate TSG-6 with OA (38). In OA, those with an
elevated TSG-6:IaI ratio have a higher risk of progres-
sion to total joint replacement (39). The magnitude of
response of either molecule following joint injury could
influence an individual’s propensity or otherwise to OA.
Findings for the other 4 molecules are consistent with
results of previous cross-sectional studies in those with
joint injury, showing elevated SF levels of IL-6 and
MCP-1 (18,23), MMP-3 (17,40,41), and TIMP-1
(16,19). Maximum levels of SF IL-1b are observed
within 24 hours after ACL rupture (18). The longer
median time to sampling of 17 days may explain the lack
of detectable IL-1 in the present study.
IL-6, TIMP-1, and TSG-6 levels were each asso-
ciated with the KOOS4 clinical score at baseline and
with the change in KOOS4 over a 3-month period. SF
IL-6 accounted for this independently, making any
additional contribution of TIMP-1 or TSG-6 redundant.
It is important to interpret these findings cautiously.
That higher measurable levels of inflammation, repre-
sented here by SF IL-6, are associated with worse clini-
cal symptoms, such as pain and loss of function, is
perhaps not surprising. However, it is noteworthy that
measurement of this single marker could, independently
of other factors, account for as much as 16% of interin-
dividual clinical variation. Sometimes simple clinical
measurements provide the same information as bio-
markers, but in this study measures such as presence of
effusion were inferior to SF IL-6. Although those with
high SF IL-6 levels were more impaired at baseline, they
reached a similar point by 3 months to those with low
IL-6 levels, suggesting that the presence of inflamma-
tion after any given injury is not an early adverse prog-
nostic factor (at least following surgical management of
the injury). It is possible that a greater inflammatory
response may predict a greater associated reparative
response by the individual, or simply that there is more
room for improvement for these individuals in this
timeframe.
The IL-6 response to injury in the joint may be
biologically important. IL-6 is synthesized by chondro-
cytes and synoviocytes, has the potential to initiate joint
damage, and can sensitize joint nociceptive C-fibers
(42). It is often elevated in SF samples from patients
with established OA and rheumatoid arthritis, and is a
therapeutic target for the latter (43). However, genetic
deletion of IL-6 has no impact on, or may even worsen,
murine OA (44,45). Alternatively, it may be that the IL-6
response is no more important than the up-regulation of
these other molecules, but its measurement most
accurately represents the overall molecular response, or
elements of this. SF IL-6 showed the highest correlation
with other analytes (including those associated with
repair), the greatest up-regulation after injury, and also
the greatest variation between individuals. Similar
features of the IL-6 response were noted after ACL rup-
ture (22). Interestingly, average pain score after meniscal
injury was associated with increased IL-6, MCP-1,
MIP-1b, or interferon-g levels in lavaged SF, but no pro-
spective data or validated patient-reported outcomes
were collected (23). In those undergoing partial menis-
cectomy, histologic synovial inflammation was associated
with worse preoperative symptoms, but not with poorer
outcomes in the first 2 years after arthroscopy (46), which
supports our findings.
Our study has some limitations. We showed that
examination of SF appears to have more utility than
examination of blood, but we were not able to systemati-
cally collect interval SF samples. Only 18 individuals
(with ongoing clinical problems) were resampled, so
analysis of this nonrepresentative subgroup was not
included. Systematic longitudinal collection of SF sam-
ples is clearly desirable when possible. The 93% rate of
SF sampling in this cohort was possible because the vast
majority of participants underwent planned early surgi-
cal interventions. Because of this, it is impossible to dis-
tinguish between the longitudinal response to injury and
the response to surgical intervention. It will be impor-
tant to examine whether the same is found in a conser-
vatively managed cohort.
Another limitation includes the relatively small
number of SF samples from controls, and the signifi-
cantly different age distributions of controls compared
with individuals with joint injury. Consideration of
“normal” biomarker levels should be tempered by this.
Controls with high levels of athletic activity would have
been preferable. The unexpected elevations in levels of
analytes such as MCP-1 in the blood of (less active)
healthy controls may reflect an “immunosuppressive”
role of high levels of athletic activity (47). Interestingly,
reduced levels of serum markers following trauma com-
pared with pretrauma levels were observed in a young,
athletic population (48).
This study has demonstrated a quantifiable cellu-
lar response to joint injury, best represented by mea-
surement of SF levels of IL-6, which varies between
individuals and is associated with clinical symptoms
measured by KOOS4 in the early period after injury. It
will be important to investigate whether any of this early
molecular response can predict clinical or radiologic
outcomes in the years after knee injury.
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